---
title: "Krishna Institute of Medical Sciences Ltd (KIMS) — Share Price, Financials & Analysis"
symbol: "KIMS"
company: "Krishna Institute of Medical Sciences Ltd"
canonical: "https://tapetide.com/stocks/KIMS"
isin: "INE967H01025"
nse_symbol: "KIMS"
bse_code: "543308"
sector: "Healthcare Services"
industry: "Hospitals"
market_cap_cr: 32155.7
generated_at: "2026-09-13T19:24:50.488Z"
---

# Krishna Institute of Medical Sciences Ltd (KIMS)

Canonical page: https://tapetide.com/stocks/KIMS

## Company

- **NSE Symbol:** KIMS
- **BSE Code:** 543308
- **ISIN:** INE967H01025
- **Sector:** Healthcare Services
- **Industry:** Hospitals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2021-06-28
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** kimshospitals.com

## About

Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.

## Latest Price

- **Price:** ₹768.95
- **Change:** -3.85 (-0.5%)
- **Open:** ₹773.95
- **Day High:** ₹776.85
- **Day Low:** ₹761.75
- **Previous Close:** ₹772.8
- **Volume:** 127766
- **As Of:** 2026-09-11T09:59:55+00:00

## Key Fundamentals

Observed at 2026-09-11T04:43:29.304990Z.

- **Market Cap:** ₹32155.7 Cr
- **Classification:** Smallcap
- **P/E (reported):** 166.9
- **P/E (TTM):** 152.27
- **EPS (TTM):** ₹5.05
- **EPS (reported):** ₹39.48
- **Book Value:** ₹89.22
- **Price to Book:** 8.66
- **Dividend Yield:** 0%
- **ROE:** 9.46%
- **ROCE:** 8.23%
- **Debt to Equity:** 1.89
- **Revenue (yearly):** ₹3930.8 Cr
- **Net Income:** ₹242 Cr
- **EBITDA:** ₹828.2 Cr
- **52-Week High:** ₹858
- **52-Week Low:** ₹575.8
- **RSI (14):** 47.74

## Tapetide Score

- **Score:** 39 / 100
- **Score date:** 2026-09-04
- **Archetype:** Expensive and Under Pressure
- **What it means:** The multiple is demanding and the trend has turned against it, without the financial strength that would justify paying up. What matters is whether the de-rating stops at the multiple or starts showing up in the numbers.
- **Pillar profile:** Quality: Average · Valuation: Expensive · Momentum: Falling
- **Percentile:** 12 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 15.21 | 9% |
| growth | 89.1 | 9% |
| momentum | 26.01 | 12% |
| ownership | 45.2 | 24% |
| quality | 53.02 | 22% |
| valuation | 17.04 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Company's median sales growth is 21.9% of last 10 years

### Weaknesses

- Stock is trading at 13.7 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.62%
- Company might be capitalizing the interest cost

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -12.2% | -1.97% | 57.64% |
| ebitda margin growth | 15.82% | -20.7% | -18.9% | -34.32% |
| net income growth | 12.99% | -41.66% | -9% | 4% |
| revenue growth | 10.12% | 28.16% | 21% | 24% |
| roce | 13.91% | -37.79% | -44.77% | 16.76% |
| roe | 12.99% | -44.84% | 14.22% | -61.18% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 652 | 606 | 634 | 688 | 777 | 772 | 797 | 872 | 961 | 998 | 1075 | 1180 |
| Expenses | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 | 799 | 868 | 956 |
| Operating Profit | 177 | 147 | 159 | 179 | 218 | 187 | 198 | 193 | 204 | 199 | 206 | 223 |
| OPM % | 27 | 24 | 25 | 26 | 28 | 24 | 25 | 22 | 21 | 20 | 19 | 19 |
| Other Income | 3 | 3 | 4 | 5 | 5 | 18 | 15 | 7 | 4 | 5 | 1 | 17 |
| Interest | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 | 57 | 68 | 83 |
| Depreciation | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 | 79 | 85 | 101 |
| Profit before tax | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 | 97 | 69 | 55 | 57 |
| Tax % | 27 | 25 | 28 | 25 | 26 | 31 | 21 | 25 | 26 | 24 | 40 | 34 |
| Net Profit | 101 | 77 | 72 | 95 | 121 | 92 | 106 | 85 | 72 | 52 | 33 | 37 |
| EPS in Rs | 2.3 | 1.8 | 1.64 | 2.16 | 2.68 | 2.22 | 2.54 | 1.96 | 1.67 | 1.33 | 1.06 | 0.99 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 664 | 918 | 1123 | 1330 | 1651 | 2198 | 2498 | 3035 | 3905 | 4212 |
| Expenses | 593 | 833 | 872 | 953 | 1126 | 1587 | 1850 | 2242 | 3090 | 3380 |
| Operating Profit | 71 | 85 | 251 | 377 | 524 | 611 | 648 | 793 | 815 | 833 |
| OPM % | 11 | 9 | 22 | 28 | 32 | 28 | 26 | 26 | 21 | 20 |
| Other Income | 37 | 6 | 5 | 9 | 27 | 41 | 13 | 43 | 17 | 28 |
| Interest | 88 | 49 | 44 | 37 | 22 | 37 | 55 | 100 | 215 | 253 |
| Depreciation | 40 | 56 | 71 | 70 | 73 | 129 | 147 | 177 | 283 | 331 |
| Profit before tax | -20 | -15 | 141 | 279 | 457 | 485 | 460 | 558 | 334 | 277 |
| Tax % | 126 | 223 | 18 | 26 | 25 | 25 | 27 | 26 | 28 | — |
| Net Profit | -46 | -49 | 115 | 205 | 344 | 366 | 336 | 415 | 242 | 194 |
| EPS in Rs | -1.32 | -1.28 | 3.2 | 5.19 | 8.32 | 8.41 | 7.75 | 9.61 | 6.03 | 5.05 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 72 | 50 | 74 | 74 | 78 | 80 | 80 | 80 | 80 | 80 |
| Reserves | 255 | -209 | 466 | 524 | 786 | 1307 | 1590 | 1748 | 2058 | 2167 |
| Borrowings | 280 | 753 | 336 | 369 | 316 | 257 | 678 | 1355 | 2562 | 4253 |
| Other Liabilities | 167 | 359 | 237 | 228 | 253 | 260 | 553 | 636 | 990 | 1190 |
| Total Liabilities | 774 | 954 | 1114 | 1194 | 1433 | 1904 | 2901 | 3820 | 5689 | 7691 |
| Fixed Assets | 518 | 755 | 863 | 916 | 931 | 1005 | 1766 | 2434 | 3348 | 5710 |
| CWIP | 64 | 0 | 0 | 2 | 9 | 21 | 477 | 600 | 1214 | 606 |
| Investments | 14 | 0 | 0 | 0 | 0 | 332 | 68 | 157 | 99 | 103 |
| Other Assets | 177 | 199 | 250 | 276 | 493 | 546 | 590 | 629 | 1028 | 1271 |
| Total Assets | 774 | 954 | 1114 | 1194 | 1433 | 1904 | 2901 | 3820 | 5689 | 7691 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 82 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 | 511 |
| Cash from Investing Activity | -100 | -64 | -110 | -125 | -354 | -412 | -416 | -753 | -1116 | -1452 |
| Cash from Financing Activity | 24 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 | 940 |
| Net Cash Flow | 5 | 3 | -3 | 32 | 12 | -26 | 36 | -15 | 9 | -1 |
| Free Cash Flow | -18 | 49 | 57 | 150 | 262 | 154 | -140 | -125 | -380 | -902 |
| CFO/OP | 80 | 192 | 195 | 102 | 104 | 86 | 87 | 102 | 91 | 81 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 59 | 59 | 49 | 43 | 30 | 28 | 42 | 43 | 48 | 52 |
| Inventory Days | 43 | 46 | 47 | 44 | 30 | 37 | — | — | — | — |
| Days Payable | 207 | 215 | 181 | 177 | 167 | 133 | — | — | — | — |
| Cash Conversion Cycle | -105 | -110 | -85 | -91 | -106 | -67 | 42 | 43 | 48 | 52 |
| Working Capital Days | 26 | -333 | -15 | -15 | -31 | -3 | 8 | -5 | -29 | -37 |
| ROCE % | 15 | 11 | 5 | 20 | 29 | 34 | 24 | 17 | 15 | 10 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 38.84% | 38.82% | 38.82% | 38.82% | 38.82% | 38.82% | 38.82% | 34.11% | 34.11% | 34.11% | 34.11% | 32.5% |
| FIIs | 14.25% | 15.27% | 16.73% | 17.84% | 15.85% | 15.68% | 15.45% | 15.54% | 15.03% | 14.33% | 14.57% | 14.44% |
| DIIs | 34.8% | 31.63% | 33.13% | 32.12% | 32.3% | 32.05% | 31.95% | 31.66% | 32.12% | 32.71% | 32.5% | 34.59% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 11.15% | 10.84% | 10.73% | 10.61% | 10.55% | 10.97% | 11.24% | 11.58% | 11.72% | 11.76% | 11.84% | 11.22% |
| Others | 0.96% | 3.43% | 0.59% | 0.61% | 2.48% | 2.48% | 2.54% | 7.11% | 7.03% | 7.09% | 6.98% | 7.25% |
| No. of Shareholders | 66957 | 71014 | 69092 | 69063 | 77617 | 95468 | 101895 | 108955 | 104872 | 101599 | 93333 | 95710 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 7 / 6 / 6

### Moving Averages — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 763.19 | Buy |
| EMA (10) | 767.22 | Buy |
| SMA (20) | 771.67 | Sell |
| EMA (20) | 772.83 | Sell |
| SMA (50) | 791.24 | Sell |
| EMA (50) | 779.82 | Sell |
| SMA (100) | 773.29 | Sell |
| EMA (100) | 765.84 | Buy |
| SMA (200) | 714.16 | Buy |
| EMA (200) | 735.96 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 45.85 | Neutral |
| MACD (12,26,9) | -7.92 | Buy |
| Stochastic (14,3,3) | 49.62 | Neutral |
| ADX (14) | 19.53 | Neutral |
| Williams %R (14) | -45.01 | Neutral |
| ATR (14) | 18.95 | Neutral |
| ROC (12) | 1.7 | Buy |
| Stoch RSI (14) | 86.86 | Sell |
| UO (7,14,28) | 40.32 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 13 | 92.86% |
| Hold | 0 | 0% |
| Sell | 1 | 7.14% |

Based on 14 analyst ratings, observed at 2026-09-11T04:43:31.153714+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-10 | [Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4b4b6457-6429-4026-9378-013c84a6d3d3.pdf) |
| 2026-09-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8e56a41-eeb0-49dc-8194-32a4199348df.pdf) |
| 2026-08-30 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=21681ba2-5d1e-4ee4-8fd7-b853d103cf85.pdf) |
| 2026-08-27 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=09a0ac3f-edc8-4366-9604-f82f79aafbc8.pdf) |
| 2026-08-26 | [Clarification Regarding Article Appearing In Dealstreetasia.Com Dated 25Th August 2026 Titled Chryscapital- Backed KIMS In Talks To Acquire Stake In Renova Hospitals For $52 Million](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1819042-1b8b-42d9-acb4-051608ea3d68.pdf) |
| 2026-08-20 | [KIMS Has Entered Into An Operations And Management Agreement And Call Option Agreement With Aurevia Hospitals Private Limited (Formerly Known As Golden Lan Solution Private Limited) Hyderabad Telangana](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d397541-9c7b-44bb-ab0f-fe790ff14c9a.pdf) |
| 2026-08-20 | [Announcement under Regulation 30 (LODR)-Allotment](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=11649dd1-e8cc-4365-acaf-b4dd1becb898.pdf) |
| 2026-08-07 | [Intimation Of Receipt Of The In-Principle Approval From BSE Limited And The National Stock Exchange Of India Limited](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e577a3de-ba41-49ca-a8a1-82b130990505.pdf) |
| 2026-08-06 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00e7a49d-c759-452d-99b6-732dc5cd1504.pdf) |
| 2026-08-05 | [24Th Annual General Meeting Of The Company Scheduled To Be Held On 27Th August 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44eada43-3579-447b-900c-28138cdb9b7a.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f825bf32-73dc-402f-81a1-3ffb31035412.pdf) |
| 2026-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b0fbbe0a-35fc-4ed0-9ddf-da65222c638f.pdf) |
| 2026-02-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=426c91b3-b646-40b0-a5c3-6659b740a2e6.pdf) |
| 2025-11-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87852130-8394-44b2-9379-218416cf1976.pdf) |
| 2025-08-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8e3f020c-994f-4490-b23e-20e263534c23.pdf) |
| 2025-02-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55f08080-dde1-4535-853a-09d070a8f29e.pdf) |
| 2024-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=392433d5-728c-4648-806a-286a8f969e1f.pdf) |
| 2024-05-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27287524-659d-486d-a4f5-5b331fc53a55.pdf) |
| 2024-02-08 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f8c891ae-f68b-44bb-9496-d1a7a21b04c7.pdf) |
| 2023-11-10 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c4117c1-1f4c-46e7-bdf4-ac04785c868d.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-04 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d31d5bec-e736-4b33-a46f-27c6383bcfad.pdf) |
| 2026-05-18 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93eddb7f-2407-4ab0-93d5-25b6430e331f.pdf) |
| 2026-02-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ce9411df-c73d-4027-b8fc-1327f5155192.pdf) |
| 2025-11-10 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6d8d183e-f15d-4e33-954e-e8ce9e8140e2.pdf) |
| 2025-08-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7f985b27-3faf-4d73-8cd0-93b3fb2776df.pdf) |
| 2024-11-11 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=faff119e-3d09-408e-8d51-78424c47bd40.pdf) |
| 2024-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aca63965-2866-4cd5-bb7a-af9e797c667c.pdf) |
| 2024-05-17 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f3a1b41d-a771-4e0f-974c-dfdb19106a83.pdf) |
| 2024-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e755005-e379-4aaf-b366-7882fa99ea59.pdf) |
| 2023-08-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1e451f5-9696-415f-8c29-268749527cf1.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-03 | [Financial Results For Q1 2026-27](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1398555a-6b99-40c9-b173-b4cee6064d9c.pdf) |
| 2026-05-15 | [Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8d7b5174-f1a9-4a79-a09e-7b132c9bbcee.pdf) |
| 2026-02-06 | [Q3FY26](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8138661d-5652-479a-b229-aeef34f1fb38.pdf) |
| 2025-11-07 | [Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5319c2c2-3a98-476a-9847-351730771892.pdf) |
| 2025-08-06 | [Results](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=46337bd3-ed47-471f-8f38-cc2543e9824c.pdf) |
| 2025-05-12 | [Results-Financial Result For The Quarter And Year Ended 31.03.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=38b298df-e3c5-4e43-b119-ecbe41abe8e5.pdf) |
| 2025-02-06 | [Quarterly Result_31St December 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2823f275-fa39-4946-ac41-d310becb3583.pdf) |
| 2024-11-09 | [Half-Year Ended 30 September 2024 Together With The Limited Review Reports As Reviewed By The Audit Committee.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7681dd5-8d5b-446a-b324-37d8a755c5a2.pdf) |
| 2024-08-07 | [Financial Results Of The Company For The 01St Quarter Ended 30Th June 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4298a23-93bb-442b-94a3-b85f530843e7.pdf) |
| 2024-05-16 | [Results - Financial Results For The FY Ended 31.03.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c0d473c-a7a5-45a0-8acf-62189a53f528.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dc25516-8e2e-4c54-b2b8-2ded7dc0388b.pdf) |
| 2026-05-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7a088671-c9a5-4286-b3b5-33801f59fccd.pdf) |
| 2026-02-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a1a208c6-041a-4186-a2fc-242d56fa1f36.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28063c0f-9bfc-4112-95fa-ddc7be2889b9.pdf) |
| 2025-11-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16f82e52-025a-4146-9ce9-41a005e7bc6e.pdf) |
| 2025-08-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=159acfe2-4c3f-4efd-abcd-95ac4b8338a3.pdf) |
| 2025-05-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dd70421f-6cd1-4400-a840-fdd39d2a2733.pdf) |
| 2025-02-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5727a7eb-349e-4a22-838c-bf7425576635.pdf) |
| 2024-11-09 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=270f2f5d-13d5-4cb6-a880-97d6e6b70a55.pdf) |
| 2024-08-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=879f0a26-f00c-47ac-a3e3-99900fd42b87.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 8 May - KIMS leased 2 acres in Amaravati for 60 years to develop a 500-bed multispeciality hospital. | [Intimation Of Entering Into A Long-Term Lease Agreement For 2 Acres Of Land For A Period Of 60 Years In Amaravati, Andhra Pradesh. 8 May - KIMS leased 2 acres in Amaravati for 60 years to develop a 500-bed multispeciality hospital.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/53e8ffd4-0d06-4e71-8870-2c406542e687.pdf) |
| 6 May - Board meeting on 15 May 2026 to approve FY26 audited standalone and consolidated results. | [Board Meeting Intimation for Board Meeting Intimation. 6 May - Board meeting on 15 May 2026 to approve FY26 audited standalone and consolidated results.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0bb17896-1ffb-4c2c-9e92-9659fcac2941.pdf) |
| 6 Mar - Board meeting on 11 March 2026 to consider QIP and/or rights issue; may call shareholders' meeting. | [Board Meeting Intimation for Prior Intimation Of Board Meeting To Be Held On 11Th March, 2026. 6 Mar - Board meeting on 11 March 2026 to consider QIP and/or rights issue; may call shareholders' meeting.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9bdb5f9a-60dd-44c7-a1ac-08dd90790768.pdf) |
| 31 Mar - Subsidiary SPANV received IT order dated 29/03/2026; demand set aside, amount payable Rs.0. | [The Subsidiary Company Has Received An Order Under Section 143(3) Read With Sections 250 And 144B Of The Income-Tax Act In Which The Department Has Set Aside The Said Demand Notice And Accordingly The Amount Payable In Respect Of This Matter Is Rs.0/- (Zero). 31 Mar - Subsidiary SPANV received IT order dated 29/03/2026; demand set aside, amount payable Rs.0.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f500ec7f-8d95-4d92-ae1f-b492a2ba4c89.pdf) |
| 23 Apr - KIMS signs non-commercial MoU with Renova for strategic oncology clinical collaboration. | [Intimation Of Entering Into Memorandum Of Understanding For Strategic Clinical Collaboration 23 Apr - KIMS signs non-commercial MoU with Renova for strategic oncology clinical collaboration.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/195f2515-5dcd-42e5-97d7-243af84aa276.pdf) |
| 20 Feb - Feb 25, 2026 'Chasing Growth 2026' investor conference by Kotak Securities in Mumbai. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 20 Feb - Feb 25, 2026 'Chasing Growth 2026' investor conference by Kotak Securities in Mumbai.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ed39d43-8f65-47e2-8471-72173d66bb20.pdf) |
| 2 Apr - KIMS subsidiary signed 20-year O&M and sub-lease agreements for 210-bed Avitis hospital in Palakkad. | [Pursuant To Provisions Of Regulation 30 Of The SEBI (LODR) Regulations, 2015, KIMS Swastha Private Limited ('The KIMS'), A Wholly-Owned Subsidiary Of Krishna Institute Of Medical Sciences Limited Has Entered Into Definitive Agreements With Avitis Super Speciality Hospitals Private Limited. 2 Apr - KIMS subsidiary signed 20-year O&M and sub-lease agreements for 210-bed Avitis hospital in Palakkad.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0f3d0a8d-fa34-44be-bfa6-514f92ab3735.pdf) |
| 17 Apr - Postal ballot approved QIP equity issuance for fund raising on April 15, 2026. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 17 Apr - Postal ballot approved QIP equity issuance for fund raising on April 15, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6b7519f8-a713-4831-93c6-f40e77c7af04.pdf) |
| 16 Mar - With DAM Capital Hospitals & Diagnostics conference | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 16 Mar - With DAM Capital Hospitals & Diagnostics conference](https://www.bseindia.com/xml-data/corpfiling/AttachHis/155c34bb-01e5-4870-b082-ddb6536ac3ad.pdf) |
| 16 Mar - QIP to raise up to Rs.1500 crore; postal ballot e-voting 17 Mar–15 Apr 2026. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 16 Mar - QIP to raise up to Rs.1500 crore; postal ballot e-voting 17 Mar–15 Apr 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6420d32a-93f9-468f-a1b6-2aba1ca66458.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/16f82e52-025a-4146-9ce9-41a005e7bc6e.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/87852130-8394-44b2-9379-218416cf1976.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cfa7e0d9-3d2e-4714-89b5-d4d78d4b4c84.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cfa7e0d9-3d2e-4714-89b5-d4d78d4b4c84.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3c4117c1-1f4c-46e7-bdf4-ac04785c868d.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3631e841-c020-463d-ae0a-a68625e4890b.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b0fbbe0a-35fc-4ed0-9ddf-da65222c638f.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/b0fbbe0a-35fc-4ed0-9ddf-da65222c638f.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7a088671-c9a5-4286-b3b5-33801f59fccd.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7a088671-c9a5-4286-b3b5-33801f59fccd.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e9524ad-fbe9-4a3d-bcb7-3881fb84f69b.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/be4f987b-e633-4160-adf1-1bfc5e2861ab.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/83bacca1-aa4f-4f38-a9c1-fd8d1a802c48.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/285b97ea-b617-4cba-b186-8d819491876f.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:24:50.488Z.